Page 2 - Liminal Bioscience News Today

/PRNewswire/ -- Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") (NASDAQ: LMNL) and Structured Alpha LP ("SALP"), a fund managed by Thomvest...

By Chris Wack Liminal BioSciences shares were up 40% at $8.32 after the company said Wednesday that Structured Alpha, a fund managed by Thomvest Asset...

By Chris Wack Liminal BioSciences said Wednesday that Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd., will buy all of the issued and...

Liminal BioSciences Inc (NASDAQ: LMNL) shares are trading higher after Structured Alpha, a fund managed by Thomvest Asset Management, agreed to 

LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General

LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. announced the voting results from its Annual General Meeting of Shareholders held virtually on June 5, 2023.... | June 5, 2023

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of...

/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting...

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)

GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide